Journal article

HFE C282Y Homozygotes Are at Increased Risk of Breast and Colorectal Cancer

Nicholas J Osborne, Lyle C Gurrin, Katrina J Allen, Clare C Constantine, Martin B Delatycki, Christine E McLaren, Dorota M Gertig, Gregory J Anderson, Melissa C Southey, John K Olynyk, Lawrie W Powell, John L Hopper, Graham G Giles, Dallas R English

HEPATOLOGY | WILEY | Published : 2010

Abstract

UNLABELLED: The evidence that mutations in the HFE gene for hemochromatosis are associated with increased cancer risk is inconsistent. The Melbourne Collaborative Cohort Study is a prospective cohort study that commenced recruitment in 1990. Participants born in Australia, New Zealand, the United Kingdom, or Ireland (n = 28,509) were genotyped for the HFE C282Y (substitution of tyrosine for cysteine at amino acid 282) variant. Incident cancers were ascertained from Australian cancer registries during an average of 14 years follow-up. Hazard ratios (HRs), confidence intervals (CIs), and P values were obtained from separate Cox regression analyses for colorectal, breast, and prostate cancers, ..

View full abstract

Grants

Awarded by National Health and Medical Research Council, Australia


Awarded by U.S. National Institutes of Health


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES


Funding Acknowledgements

The research was funded by grants from the National Health and Medical Research Council, Australia (251668, 209057), and the U.S. National Institutes of Health (5-R01-DK-061885-03). J.K.O. and M.B.D. are the recipients of Practitioner Fellowships, G.A. is Senior Research Fellow. J.L.H. is the recipient of an Australia Fellowship, and L.C.G. and K.J.A. are the recipients of Career Development Awards, all from the Australian National Health and Medical Research Council.